1 to 9 of 10 results

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals


In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Daiichi Sankyo sets out five-year plan to overcome Olmetec patent expiry


Japanese drug major Daiichi Sankyo (TYO: 4568) has announced a new five-year Business Plan, which will…

Daiichi SankyoFinancialolmesartanOlmetecPatentsPharmaceuticalRanbaxy Laboratories

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA


The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Ring in generics in 2012 and beyond, says Zacks Equity Research


The New Year is expected to be a happy beginning for generic companies like Teva Pharmaceuticals (Nasdaq:…

Dr Reddy's LaboratoriesGenericsMarkets & MarketingNorth AmericaPatentsRanbaxy LaboratoriesSandozTeva Pharmaceutical IndustriesWatson Pharmaceuticals

US launch of generic Lipitor confirms value of competition, says GPhA


Commenting on this week’s US roll out for generic copies of Pfizer blockbuster cholesterol lowerer…

GenericsLipitorMarkets & MarketingNorth AmericaPatentsPfizerRanbaxy LaboratoriesWatson Pharmaceuticals

Takeda settles Actos patent law suits with Mylan, Watson and Ranbaxy, as well as Teva and others


Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502), and its US subsidiary have completed…

DiabetesGenericsLegalMylan LaboratoriesPatentsRanbaxy LaboratoriesTakeda PharmaceuticalsTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Outlook for generic equivalent of Pfizer’s Lipitor; how will US exclusivity resolve? asks law firm HPM


2011 is shaping up to be an interesting year in the Hatch-Waxman world, and all eyes seem to be focusing…

AriceptatorvastatinCardio-vascularFlomaxGenericsLipitorNorth AmericaPatentsPfizerPharmaceuticalRanbaxy LaboratoriesRegulation

1 to 9 of 10 results



Back to top